Refine
Has Fulltext
- yes (33)
Is part of the Bibliography
- yes (33)
Year of publication
Document Type
- Journal article (32)
- Doctoral Thesis (1)
Keywords
- Immunologie (12)
- measles virus (5)
- Lymphozyt (4)
- sphingolipids (4)
- SARS-CoV-2 (3)
- ceramides (3)
- acid ceramidase inhibitor ceranib-2 (2)
- acid sphingomyelinase (2)
- ceramide (2)
- peripheral nervous system (2)
Institute
- Institut für Virologie und Immunbiologie (33)
- Institut für Organische Chemie (6)
- Theodor-Boveri-Institut für Biowissenschaften (4)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (1)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (1)
- Lehrstuhl für Tissue Engineering und Regenerative Medizin (1)
- Neurologische Klinik und Poliklinik (1)
Recently, we have shown that C6-ceramides efficiently suppress viral replication by trapping the virus in lysosomes. Here, we use antiviral assays to evaluate a synthetic ceramide derivative α-NH2-ω-N3-C6-ceramide (AKS461) and to confirm the biological activity of C6-ceramides inhibiting SARS-CoV-2. Click-labeling with a fluorophore demonstrated that AKS461 accumulates in lysosomes. Previously, it has been shown that suppression of SARS-CoV-2 replication can be cell-type specific. Thus, AKS461 inhibited SARS-CoV-2 replication in Huh-7, Vero, and Calu-3 cells up to 2.5 orders of magnitude. The results were confirmed by CoronaFISH, indicating that AKS461 acts comparable to the unmodified C6-ceramide. Thus, AKS461 serves as a tool to study ceramide-associated cellular and viral pathways, such as SARS-CoV-2 infections, and it helped to identify lysosomes as the central organelle of C6-ceramides to inhibit viral replication.